<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="groups are defined by each of their members having acquired" exact="infection" post="through a specific behavior. However, risk group definitions say"/>
 <result pre="infectious disease, the mean number of secondary infections per primary" exact="infection" post="in a completely susceptible population [4] (for notations see"/>
 <result pre="time between the primary and secondary infections, typically termed the" exact="infection" post="generation time (T; several other definitions are used in"/>
 <result pre="months or years. Here we show how transmission variability and" exact="infection" post="generation time can be estimated by combining viral genomic"/>
 <result pre="the same population. First, we used inferred HCV incidence and" exact="prevalence" post="by subtype from previous studies [25]. Next, we used"/>
 <result pre="chronically infected with HCV. The majority of patients with HCV" exact="infection" post="develop persistent or chronic infection (60–92%) whilst a minority"/>
 <result pre="majority of patients with HCV infection develop persistent or chronic" exact="infection" post="(60–92%) whilst a minority clears HCV-RNA (8–40%); viral clearance"/>
 <result pre="clearance is much faster within the first 2 years of" exact="infection" post="and slower thereafter (≪1% per year), while increased rates"/>
 <result pre="younger age, female gender, lack of HIV co-infection, chronic HBV" exact="infection" post="and genetic variation in IL28B [29]–[42]. HCV phylodynamic analysis"/>
 <result pre="while for subtype 1b and 4a infections the source of" exact="infection" post="was usually unknown. These distributions are consistent with previous"/>
 <result pre="rapid spread. HCV is hyperendemic in IDUs worldwide with anti-HCV" exact="prevalence" post="of 15–90% [45]; IDUs may share syringes, needles and"/>
 <result pre="tracking of secondary infections is very difficult and date of" exact="infection" post="is in most cases unknown. Some workers have suggested"/>
 <result pre="the duration of infectiousness (∼12.5 years). The probability of secondary" exact="infection" post="per contact is expected to be higher during the"/>
 <result pre="when viral load is 10 times greater than later in" exact="infection" post="[55], [56]. Also, in the first year patients are"/>
 <result pre="Estimated distributions of the number of secondary infections per primary" exact="infection" post="for each HCV subtype. Figure 5 Cumulative proportion of"/>
 <result pre="for each HCV subtype. Figure 5 Cumulative proportion of onward" exact="infection" post="versus the infected population ranked by the number of"/>
 <result pre="the rate of coalescence (Ne), viral generation time (T), and" exact="prevalence" post="(N) and thus is independent of phylogenetic topology. It"/>
 <result pre="Athens University Medical School. Estimation of chronic HCV incidence and" exact="prevalence" post="through time The overall and genotype-specific incidence of chronic"/>
 <result pre="through time The overall and genotype-specific incidence of chronic HCV" exact="infection" post="has been estimated in previous studies using back-calculation [24],"/>
 <result pre="infected individuals was obtained from 943 Greek patients enrolled in" exact="treatment" post="studies [24], [25]. Enrolment took place between 1995 and"/>
 <result pre="2000; patients were adults (18–70 years old) with a histological" exact="diagnosis" post="of chronic hepatitis. Injecting drug use, transfusion, other and"/>
 <result pre="of the patients, respectively. The distribution of the dates of" exact="infection" post="within each transmission group was determined using data from"/>
 <result pre="was determined using data from 456 Greek patients enrolled in" exact="treatment" post="studies with known dates of infection. We extended the"/>
 <result pre="to obtain an estimate of the overall genotype-specific incidence and" exact="prevalence" post="during 1940–1990. HCV sequence data Correct sampling is crucial"/>
 <result pre="recorded for each sample: patient's age, sex, transmission group and" exact="treatment" post="history (Table S1). Samples were excluded where the patient"/>
 <result pre="exponential phase as 1990, to reflect the introduction of anti-HCV" exact="screening" post="after the virus' discovery in 1989. The start of"/>
 <result pre="et al. (1999) Prevalence and clinical outcome of hepatitis C" exact="infection" post="in children who underwent cardiac surgery before the implementation"/>
 <result pre="Straley-EasonKD, et al. (2000) 45-year follow-up of hepatitis C virus" exact="infection" post="in healthy young adults. Ann Intern Med132: 105–111.10644270 35SantantonioT,"/>
 <result pre="Infect Dis43: 1154–1159.17029134 36Kenny-WalshE (1999) Clinical outcomes after hepatitis C" exact="infection" post="from contaminated anti-D immune globulin. Irish Hepatology Research Group."/>
 <result pre="1899–1905.1280771 41AlterMJ, Kruszon-MoranD, NainanOV, McQuillanGM, GaoF, et al. (1999) The" exact="prevalence" post="of hepatitis C virus infection in the United States,"/>
 <result pre="GaoF, et al. (1999) The prevalence of hepatitis C virus" exact="infection" post="in the United States, 1988 through 1994. N Engl"/>
 <result pre="PougetER, Des JarlaisDC, Lelutiu-WeinbergerC (2008) Meta-regression of hepatitis C virus" exact="infection" post="in relation to time since onset of illicit drug"/>
 <result pre="OrphanouE, LallaTH, LitaA, GarifallosA (2001) Prevalence of hepatitis C virus" exact="infection" post="in a cohort of pregnant women in northern Greece"/>
 <result pre="HadjipaschaliE, HatzakisA (2001) Prevalence, risk factors and evaluation of a" exact="screening" post="strategy for chronic hepatitis C and B virus infections"/>
 <result pre="721–728.12086089 52GoritsasC, PlerouI, AgaliotisS, SpinthakiR, MimidisK, et al. (2000) HCV" exact="infection" post="in the general population of a Greek island: prevalence"/>
 <result pre="HCV infection in the general population of a Greek island:" exact="prevalence" post="and risk factors. Hepato-Gastroenterology47: 782–785.10919032 53CornbergM, RazaviHA, AlbertiA, BernasconiE,"/>
 <result pre="EvansJ, ShiboskiS, LumP, et al. (2009) Acute hepatitis C virus" exact="infection" post="in young adult injection drug users: a prospective study"/>
 <result pre="2617–2626.18809775 60ChungH, UedaT, KudoM (2010) Changing trends in hepatitis C" exact="infection" post="over the past 50 years in Japan. Intervirology53: 39–43.20068339"/>
</results>
